Merger Of Pfizer, Allergan Draws Ire From Lawmakers Worried About Drug Prices, Tax Loss

November 23, 2015 at 6:05 PM
A merger between two pharmaceutical heavyweights -- New York-based Pfizer and Dublin-based Allergan -- is making history as the largest inversion transaction, but is drawing scrutiny from Capitol Hill and the campaign trail for the same reason. Democratic presidential candidates complained the merger could raise U.S. drug prices while sending tax dollars overseas, and key lawmakers seized the opportunity to push for overhaul of the U.S. tax code. But Pfizer defended the deal as a pro-consumer move aimed at creating...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.